Could cause temporary or reversible harm; serious harm is unlikely.
Discoloration: Dotted and yellow spots on tablets
| Brand name | CLORAZEPATE DIPOTASSIUM |
| Generic name | CLORAZEPATE DIPOTASSIUM |
| Active ingredient(s) | CLORAZEPATE DIPOTASSIUM |
| Distributed by / for | Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520 |
| NDC | 13107-282-01 |
| Full product label | Clorazepate Dipotassium Tablets, USP, 3.75 mg, a) 100 tablets per bottle, NDC 13107-282-01 b) 500 tablets per bottle, NDC 13107-282-05, Rx Only, Distributed by Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India. |
| Recalling firm | Aurobindo Pharma USA Inc. |
| Distribution | Nationwide in the USA |
| Quantity | 6696 bottles |
| Recall initiated | 2024-04-24 |
| Report date | 2024-05-15 |
| Recall completed | — |
| Recall number | D-0491-2024 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | East Windsor NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗